<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351610</url>
  </required_header>
  <id_info>
    <org_study_id>MSC_Apceth_001</org_study_id>
    <nct_id>NCT01351610</nct_id>
  </id_info>
  <brief_title>Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia</brief_title>
  <official_title>Open, Randomized, Mono-Centre, Two-Parallel Group Clinical Phase I/II Trial on the Evaluation of Tolerability and Efficacy of an Intravenous Infusion of Human Bone Marrow Derived Autologous, CD34-Negative Mesenchymal Stem Cells for the Treatment of Critical Limb Ischemia in Patients With Advanced Peripheral Arterial Occlusive Disease Subsequent to Percutaneous Transluminal Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apceth GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apceth GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MSC_Apceth are GMP-manufactured, autologous ex-vivo expanded non-hemapoietic bone-marrow
      derived stem cells for the treatment of Critical Limb Ischemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collection of adverse events</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory values</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG findings</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of inflammation markers</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of course of haemodynamic and vascular processes</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PTA + Infusion of MSC_Apceth</intervention_name>
    <description>percutaneous transluminal angioplasty followed by infusion of MSC_Apceth</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PTA</intervention_name>
    <description>percutaneous transluminal angioplasty only</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with peripheral arterial occlusive disease (symptomatic PAOD), diagnosis of
             CLI defined as persistent, recurring ischemic rest pain for at least 2 weeks, and/or
             ulceration or gangrene of the foot or toe, with an ABPI &lt;/= 0.5,

          2. Patients with staging of ≥III according to Fontaine and ≥4 according to Rutherford
             categories,

          3. Patients fulfilling the criteria for an invasive re-vascularisation procedure (PTA) at
             the discretion of the investigator,

          4. Patients without major amputation of the lower extremities within the period of 6
             months after inclusion in the opinion of the investigator,

        Exclusion Criteria:

          1. Patients with wounds of a severity of greater than grade 2 on the Wagner Scale,

          2. Patients with life-threatening ventricular arrhythmia,

          3. Patients with unstable angina pectoris,

          4. Patients with severe congestive heart failure (i.e. NYHA Stage IV),

          5. Patients with uncontrolled hypertension (defined as diastolic blood pressure &gt;110 mmHg
             or systolic blood pressure &gt;180 mmHg during screening),

          6. Patients with an uncontrolled diabetes mellitus (HbA1c &gt; 9%),

          7. Patients having any history of malignant tumour in the anamnesis or are currently on
             tumour treatment,

          8. Patients who are unsuitable for a MSC stem cell therapy in the opinion of the
             investigator,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Heider, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isar Medizin Zentrum, München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isar Medizin Zentrum</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Limb Ischemia</keyword>
  <keyword>Peripheral Arterial Occlusive Disease</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>Stem Cell Therapy</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

